Tai, Yu-Tzu
Lin, Liang
Xing, Lijie
Cho, Shih-Feng
Yu, Tengteng
Acharya, Chirag
Wen, Kenneth
Hsieh, Phillip A.
Dulos, John
van Elsas, Andrea
Munshi, Nikhil
Richardson, Paul
Anderson, Kenneth C.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50-100007, PO1-155258, RO1-124929, P50-100007, RO1-50947, RO1-124929, P50-100007, RO1-50947)
Article History
Received: 7 May 2018
Revised: 16 July 2018
Accepted: 23 July 2018
First Online: 22 August 2018
Compliance with ethical standards
:
: N.C.M. serves on advisory boards to Millennium, Celgene, and Novartis. K.C.A. serves on advisory boards Celgene, Millennium and Gilead Sciences and is a Scientific founder of OncoPep and C4 Therapeutics. P.R. is on advisory board of Celgene, Millennium and Johnson & Johnson. J.D. and A.v.E. are employees of Aduro Biotech Europe. The remaining authors declare that they have no conflict of interest.